Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sunho Biologics,Inc. ( (HK:2898) ) has shared an announcement.
Sunho Biologics, Inc. has announced its audited consolidated annual results for 2024, revealing a decrease in losses compared to 2023. The company reported significant advancements in its R&D capabilities, particularly with its core product IAH0968, which targets HER2 and enhances immune response through ADCC, positioning Sunho Biologics as a significant player in the oncology treatment landscape.
More about Sunho Biologics,Inc.
Sunho Biologics, Inc. is a clinical stage biopharmaceutical company founded in 2018, focusing on the discovery, development, and commercialization of biologics for treating cancers and autoimmune diseases. The company has developed three core products: IAH0968, IAP0971, and IAE0972, with IAH0968 being an ADCC enhanced monoclonal antibody currently in Phase II clinical trials for various cancers.
YTD Price Performance: 13.30%
Average Trading Volume: 7,090
Technical Sentiment Signal: Strong Buy
Learn more about 2898 stock on TipRanks’ Stock Analysis page.